Soligenix, Inc. to Showcase 2022 Milestones in Enterprise Replace Hearth Chat with PCG Advisory

Angelena Iglesia

Interview to be webcast on November 29, 2022 at 11:00 am ET

New York, NY – (NewMediaWire) – November 16, 2022 – Soligenix, Inc., (Nasdaq: SNGX) (the “Firm” or “Soligenix”), a late-stage biopharmaceutical firm centered on creating and commercializing merchandise to deal with uncommon ailments the place there’s an unmet medical want, will be part of PCG Advisory for a Hearth Chat on November 29 at 11:00 am ET.

To register for the webcast and entry the replay of the interview please click on: https://us06web.zoom.us/webinar/register/WN_bIGC3Z_OT5q8RVoQvlMfwg.

Soligenix President and Chief Govt Officer, Dr. Christopher J. Schaber, will talk about the numerous milestones achieved by the corporate throughout 2022 and can check out what buyers can count on to see within the coming quarter.

“Soligenix has had a transformational 12 months in 2022, with extra vital milestones anticipated earlier than the tip of This fall,” said Christopher J. Schaber, PhD, President and Chief Govt Officer of Soligenix. “The outcomes of our profitable Section 3 research evaluating HyBryte(TM) (artificial hypericin) for the therapy of cutaneous T-cell lymphoma (CTCL) had been revealed within the prestigious JAMA Dermatology and the FDA awarded a $2.6 million grantfor an expanded research of HyBryte(TM). Soligenix was additionally invited to submit a contract proposal for vaccine growth by the Biomedical Superior Analysis and Improvement Authority (BARDA).

“We count on to submit our new drug utility (NDA) utility to the FDA for HyBryte(TM) throughout this quarter. Moreover, we’re persevering with our growth into new illness indications with artificial hypericin having obtained FDA investigational new drug (IND) clearance for a Section 2a scientific trial in mild-to-moderate psoriasis, additionally anticipated to start earlier than 12 months finish.

“We look ahead to taking part within the PCG Advisory Hearth Chat and sharing among the 12 months’s highlights with buyers.”

Soligenix was lately featured in an interview on New To The Road which was broadcast on FOX Enterprise.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical firm centered on creating and commercializing merchandise to deal with uncommon ailments the place there’s an unmet medical want. Our Specialised BioTherapeutics enterprise phase is creating and transferring towards potential commercialization of HyBryte(TM) (SGX301 or artificial hypericin) as a novel photodynamic remedy using secure seen gentle for the therapy of cutaneous T-cell lymphoma (CTCL). With a profitable Section 3 research accomplished, regulatory approval is being sought and commercialization actions for this product candidate are being superior initially within the U.S. Improvement packages on this enterprise phase additionally embody growth of artificial hypericin (SGX302) into psoriasis, our first-in-class innate protection regulator (IDR) know-how, dusquetide (SGX942) for the therapy of inflammatory ailments, together with oral mucositis in head and neck most cancers, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/therapy of gastrointestinal (GI) issues characterised by extreme irritation together with pediatric Crohn’s illness (SGX203).

Our Public Well being Options enterprise phase contains energetic growth packages for RiVax(R), our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and rising infectious illness, and our vaccine packages focusing on filoviruses (comparable to Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (brought on by SARS-CoV-2). The event of our vaccine packages incorporates the usage of our proprietary warmth stabilization platform know-how, often called ThermoVax(R). To this point, this enterprise phase has been supported with authorities grant and contract funding from the Nationwide Institute of Allergy and Infectious Ailments (NIAID), the Protection Menace Discount Company (DTRA) and the Biomedical Superior Analysis and Improvement Authority (BARDA).

For additional info relating to Soligenix, Inc., please go to the Firm’s web site at https://www.soligenix.com and comply with us on LinkedIn and Twitter at @Soligenix_Inc.

About PCG Advisory

PCG Advisory is a number one investor relations agency devoted to the supply of top-tier strategic providers that embody investor relations, capital markets navigation, and company communications for revolutionary and rising corporations from across the globe. PCG Advisory has in depth expertise with life science, fintech and blockchain know-how corporations. PCG Advisory is a part of PCG Holdings Inc., a holding firm for a community of assets devoted to the invention and creation of worth within the small and micro-cap fairness market that was based in 2008. All subsidiaries of PCG Holdings are geared towards serving to buyers establish worth the place it’s not most blatant by facilitating a dynamic movement of knowledge between its shoppers and the funding group. PCG Holdings working subsidiaries additionally contains PCG Digital and PCG Video. PCG Digital owns, companions with and/or licenses revolutionary aggregation, distribution, and engagement platforms. PCG Digital reaches 1000’s of particular person, retail and institutional buyers and stakeholders via its proprietary and in depth distribution community in addition to via the usage of distinctive multimedia advertising and viewers growth methods. PCG Video produces administration interviews and spotlight and informational clips to additional improve and showcase our shopper corporations. Movies are filmed at strong manufacturing assets in PCG’s NYC workplace. For extra info, please go to: www.pcgadvisory.com.

This press launch could comprise forward-looking statements that replicate Soligenix, Inc.’s present expectations about its future outcomes, efficiency, prospects and alternatives, together with however not restricted to, potential market sizes, affected person populations and scientific trial enrollment. Statements that aren’t historic information, comparable to “anticipates,” “estimates,” “believes,” “hopes,” “intends,” “plans,” “expects,” “aim,” “could,” “recommend,” “will,” “potential,” or comparable expressions, are forward-looking statements. These statements are topic to plenty of dangers, uncertainties and different components that would trigger precise occasions or leads to future intervals to vary materially from what’s expressed in, or implied by, these statements, comparable to skilled with the COVID-19 outbreak. Soligenix can not guarantee you that it is going to be in a position to efficiently develop, obtain regulatory approval for or commercialize merchandise based mostly on its applied sciences, notably in gentle of the numerous uncertainty inherent in creating therapeutics and vaccines in opposition to bioterror threats, conducting preclinical and scientific trials of therapeutics and vaccines, acquiring regulatory approvals and manufacturing therapeutics and vaccines, that product growth and commercialization efforts is not going to be diminished or discontinued attributable to difficulties or delays in scientific trials or attributable to lack of progress or optimistic outcomes from analysis and growth efforts, that it is going to be in a position to efficiently receive any additional funding to assist product growth and commercialization efforts, together with grants and awards, preserve its present grants that are topic to efficiency necessities, enter into any biodefense procurement contracts with the U.S. Authorities or different international locations, that it is going to be in a position to compete with bigger and higher financed rivals within the biotechnology trade, that modifications in well being care apply, third get together reimbursement limitations and Federal and/or state well being care reform initiatives is not going to negatively have an effect on its enterprise, or that the U.S. Congress could not go any laws that would offer extra funding for the Venture BioShield program. As well as, there may be no assurance as to the timing or success of any of its scientific/preclinical trials. Regardless of the statistically vital consequence achieved within the HyBryte(TM) (SGX301) Section 3 scientific trial for the therapy of cutaneous T-cell lymphoma, there may be no assurance {that a} advertising authorization from the FDA or EMA will probably be profitable. However the consequence within the HyBryte(TM) (SGX301) Section 3 scientific trial for the therapy of cutaneous T-cell lymphoma and the Section 1/2 proof-of-concept scientific trial of SGX302 for the therapy of psoriasis, there may be no assurance as to the timing or success of the scientific trials of SGX302 for the therapy of psoriasis. Additional, there may be no assurance that RiVax(R) will qualify for a biodefense Precedence Evaluate Voucher (PRV) or that the prior gross sales of PRVs will probably be indicative of any potential gross sales value for a PRV for RiVax(R). Additionally, no assurance may be offered that the Firm will obtain or proceed to obtain non-dilutive authorities funding from grants and contracts which were or could also be awarded or for which the Firm will apply sooner or later. These and different threat components are described occasionally in filings with the Securities and Alternate Fee, together with, however not restricted to, Soligenix’s reviews on Types 10-Q and 10-Okay. Until required by regulation, Soligenix assumes no obligation to replace or revise any forward-looking statements on account of new info or future occasions.

Investor Relations:
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
(646) 823-8656
www.pcgadvisory.com

View the unique launch on www.newmediawire.com

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

As recession looms, British enterprise sends out lending SOS

Breadcrumb Path Hyperlinks PMN Expertise PMN Enterprise Creator of the article: Reuters Sinead Cruise and Iain Withers and Lawrence White Publishing date: Nov 17, 2022  •  4 hours in the past  •  4 minute learn Be part of the dialog Article content material LONDON — As inflation rockets and recession looms, […]
As recession looms, British enterprise sends out lending SOS

Subscribe US Now